In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation
CMV associated tissue-invasive disease is associated with a considerable risk of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Recently, the terminase inhibitor letermovir (LMV) has been approved for prophylaxis of CMV infection in HSCT. We hereby report a...
Saved in:
Main Authors: | Jochen J Frietsch, Detlef Michel, Thomas Stamminger, Friederike Hunstig, Sebastian Birndt, Ulf Schnetzke, Sebastian Scholl, Andreas Hochhaus, Inken Hilgendorf |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2019-01-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | https://www.mjhid.org/index.php/mjhid/article/view/3708 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM?
by: Fabian Herrera
Published: (2024-04-01) -
Determination of whole genome sequence of human cytomegalovirus circulating in Japan and discovery of geographic genome structure in UL148 gene
by: Yuji Wada, et al.
Published: (2025-03-01) -
Refractory human cytomegalovirus infection without evidence of genetic resistance in the UL-54 and UL-97 genes in a pediatric hematopoietic stem cell transplant recipient: a case report
by: Alejandra Pando-Caciano, et al.
Published: (2024-02-01) -
Corrigendum: Refractory human cytomegalovirus infection without evidence of genetic resistance in the UL-54 and UL-97 genes in a pediatric hematopoietic stem cell transplant recipient: a case report
by: Alejandra Pando-Caciano, et al.
Published: (2025-01-01) -
ID222 Análise de custo-efetividade e impacto orçamentário do letermovir como profilaxia da infecção e doença por citomegalovírus em pacientes adultos soropositivos (CMV R+) receptores de transplante de células-tronco hematopoiéticas alogênico, na perspectiva do Sistema Único de Saúde
by: Álex Brunno do Nascimento Martins, et al.
Published: (2024-11-01)